Byeong Hwa Jeon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Byeong Hwa Jeon has a total of 558 co-authors. Here are the top co-authors by number of shared publications:
- Cuk-Seong Kim
Department of Physiology & Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea
56 shared publications - Jin Bong Park
Laboratory of Veterinary Pharmacology, College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University
44 shared publications Hee Kyoung Joo
Department of Physiology, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea; Research Institute of Medical Sciences, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea
39 shared publicationsYu Ran Lee
Department of Physiology, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea; Research Institute of Medical Sciences, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea
38 shared publicationsSunga Choi
Research Institute of Medical Sciences, Department of Physiology, School of Medicine, Chungnam National University, Daejeon, South Korea
31 shared publicationsMyoung Soo Park
Research Institute of Medical Sciences, Department of Physiology, School of Medicine, Chungnam National University, Daejeon, South Korea
25 shared publications
Latest Publications
- Open Access
- 28 July 2026
- Published by Elsevier in SSRN Electronic Journal
miR-378a-5p promotes MASLD progression by suppressing SIRT5-mediated mitochondrial homeostasis
Metabolic dysfunction-associated steatotic liver disease (MASLD) is driven by hepatic lipid overload, mitochondrial dysfunction, and oxidative stress. However, the post-transcriptional mechanisms that couple lipid excess to mitochondrial injury remain incompletely understood. Here, we identify microRNA-378a-5p (miR-378a-5p) as a lipid overload-induced suppressor of sirtuin 5 (SIRT5), a mitochondrial NAD+-dependent deacylase that maintains redox and metabolic homeostasis. Fatty acid (FA)-induced lipid overload in HepG2 cells promoted lipid accumulation, increased mitochondrial reactive oxygen species ROS (mtROS) production, loss of mitochondrial membrane potential, impaired fatty acid β-oxidation (FAO), and reduced expression of oxidative phosphorylation-related proteins. Under these conditions, SIRT5 exhibited discordant regulation, with increased mRNA expression but decreased protein abundance. Analysis of publicly available datasets (GSE114923 and GSE185062), together with experimental validation, revealed that miR-378a-5p was consistently upregulated in FA-treated hepatocytes and the livers of high-fat diet (HFD)-fed mice. Mechanistically, miR-378a-5p directly targeted a conserved site within the SIRT5 coding sequence (CDS), thereby suppressing SIRT5 protein expression. Inhibition of miR-378a-5p restored SIRT5 expression, reduced mtROS production, improved FAO, and attenuated lipid accumulation, whereas SIRT5 knockdown abolished these protective effects. In HFD-fed mice, systemic inhibition of miR-378a-5p restored hepatic SIRT5 protein expression, improved serum markers of liver injury and lipid metabolism, and reduced hepatic steatosis. Collectively, these findings highlight the miR-378a-5p–SIRT5 axis as a post-transcriptional mechanism linking lipid overload to mitochondrial dysfunction and MASLD progression and suggest that miR-378a-5p inhibition may represent a promising therapeutic strategy for restoring mitochondrial metabolic homeostasis in fatty liver disease.
- 28 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessmiR-378a-5p promotes MASLD progression by suppressing SIRT5-mediated mitochondrial homeostasis
Metabolic dysfunction-associated steatotic liver disease (MASLD) is driven by hepatic lipid overload, mitochondrial dysfunction, and oxidative stress. However, the post-transcriptional mechanisms that couple lipid excess to mitochondrial injury remain incompletely understood. Here, we identify microRNA-378a-5p (miR-378a-5p) as a lipid overload-induced suppressor of sirtuin 5 (SIRT5), a mitochondrial NAD+-dependent deacylase that maintains redox and metabolic homeostasis. Fatty acid (FA)-induced lipid overload in HepG2 cells promoted lipid accumulation, increased mitochondrial reactive oxygen species ROS (mtROS) production, loss of mitochondrial membrane potential, impaired fatty acid β-oxidation (FAO), and reduced expression of oxidative phosphorylation-related proteins. Under these conditions, SIRT5 exhibited discordant regulation, with increased mRNA expression but decreased protein abundance. Analysis of publicly available datasets (GSE114923 and GSE185062), together with experimental validation, revealed that miR-378a-5p was consistently upregulated in FA-treated hepatocytes and the livers of high-fat diet (HFD)-fed mice. Mechanistically, miR-378a-5p directly targeted a conserved site within the SIRT5 coding sequence (CDS), thereby suppressing SIRT5 protein expression. Inhibition of miR-378a-5p restored SIRT5 expression, reduced mtROS production, improved FAO, and attenuated lipid accumulation, whereas SIRT5 knockdown abolished these protective effects. In HFD-fed mice, systemic inhibition of miR-378a-5p restored hepatic SIRT5 protein expression, improved serum markers of liver injury and lipid metabolism, and reduced hepatic steatosis. Collectively, these findings highlight the miR-378a-5p–SIRT5 axis as a post-transcriptional mechanism linking lipid overload to mitochondrial dysfunction and MASLD progression and suggest that miR-378a-5p inhibition may represent a promising therapeutic strategy for restoring mitochondrial metabolic homeostasis in fatty liver disease.
- Open Access
- 30 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (13) , 5918
Mitochondrial Immunometabolism in Sepsis: From Oxidative Stress and mtDAMP Signaling to Biomarker-Guided Therapy
Sepsis is a life-threatening syndrome characterized by a dysregulated host response to infection and progressive organ dysfunction. Although early antimicrobial therapy, source control, hemodynamic resuscitation, and organ support remain the foundations of care, these approaches do not directly reverse the cellular mechanisms that connect systemic inflammation to multi-organ failure. Mitochondrial dysfunction has emerged as a central mechanism linking impaired oxygen utilization, oxidative and nitrosative stress, immune-cell metabolic reprogramming, inflammatory amplification, and organ injury. During sepsis, inflammatory mediators, nitric oxide, microcirculatory abnormalities, calcium dysregulation, and metabolic stress converge on mitochondria, impairing oxidative phosphorylation and promoting mitochondrial reactive oxygen species/reactive nitrogen species (ROS/RNS) generation. When mitochondrial quality-control programs, including fission, fusion, mitophagy, and mitochondrial biogenesis, fail to restore network integrity, damaged mitochondria accumulate and become persistent sources of oxidative stress and danger signals. Mitochondrial damage-associated molecular patterns, particularly mitochondrial DNA, oxidized mitochondrial DNA, cardiolipin, ATP, and N-formyl peptides, activate innate immune pathways such as TLR9-MyD88-NF-kappaB, the NLRP3 inflammasome, and cGAS-STING signaling. In parallel, mitochondrial metabolism shapes macrophage activation, neutrophil function, T-cell competence, pyruvate-lactate handling through the pyruvate dehydrogenase complex, and the transition between hyperinflammation and immunosuppression. Clinical translation remains challenging because sepsis is biologically heterogeneous and mitochondrial dysfunction is dynamic, tissue-specific, and influenced by disease stage. This review synthesizes current knowledge on mitochondrial dysfunction in sepsis, emphasizing oxidative and nitrosative stress, mitochondrial quality control, mitochondrial damage-associated molecular pattern (DAMP) signaling, immunometabolism, organ-specific injury, candidate biomarkers, clinical translational strategies for mitochondria-targeted therapy, and future approaches based on multi-omics and artificial intelligence-assisted patient stratification. We argue that future therapeutic development should move beyond nonspecific antioxidant supplementation toward time-sensitive, phenotype-informed, and biomarker-guided mitochondrial medicine.
- 30 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (13) , 5918
Open AccessMitochondrial Immunometabolism in Sepsis: From Oxidative Stress and mtDAMP Signaling to Biomarker-Guided Therapy
Sepsis is a life-threatening syndrome characterized by a dysregulated host response to infection and progressive organ dysfunction. Although early antimicrobial therapy, source control, hemodynamic resuscitation, and organ support remain the foundations of care, these approaches do not directly reverse the cellular mechanisms that connect systemic inflammation to multi-organ failure. Mitochondrial dysfunction has emerged as a central mechanism linking impaired oxygen utilization, oxidative and nitrosative stress, immune-cell metabolic reprogramming, inflammatory amplification, and organ injury. During sepsis, inflammatory mediators, nitric oxide, microcirculatory abnormalities, calcium dysregulation, and metabolic stress converge on mitochondria, impairing oxidative phosphorylation and promoting mitochondrial reactive oxygen species/reactive nitrogen species (ROS/RNS) generation. When mitochondrial quality-control programs, including fission, fusion, mitophagy, and mitochondrial biogenesis, fail to restore network integrity, damaged mitochondria accumulate and become persistent sources of oxidative stress and danger signals. Mitochondrial damage-associated molecular patterns, particularly mitochondrial DNA, oxidized mitochondrial DNA, cardiolipin, ATP, and N-formyl peptides, activate innate immune pathways such as TLR9-MyD88-NF-kappaB, the NLRP3 inflammasome, and cGAS-STING signaling. In parallel, mitochondrial metabolism shapes macrophage activation, neutrophil function, T-cell competence, pyruvate-lactate handling through the pyruvate dehydrogenase complex, and the transition between hyperinflammation and immunosuppression. Clinical translation remains challenging because sepsis is biologically heterogeneous and mitochondrial dysfunction is dynamic, tissue-specific, and influenced by disease stage. This review synthesizes current knowledge on mitochondrial dysfunction in sepsis, emphasizing oxidative and nitrosative stress, mitochondrial quality control, mitochondrial damage-associated molecular pattern (DAMP) signaling, immunometabolism, organ-specific injury, candidate biomarkers, clinical translational strategies for mitochondria-targeted therapy, and future approaches based on multi-omics and artificial intelligence-assisted patient stratification. We argue that future therapeutic development should move beyond nonspecific antioxidant supplementation toward time-sensitive, phenotype-informed, and biomarker-guided mitochondrial medicine.
- 5 March 2026
- Published by Elsevier in Cellular Signalling
- Vol. 143, 112470
APE1/Ref-1 redox function prevents VSMC phenotypic switching through KLF4 suppression
- 5 March 2026
- Published by Elsevier in Cellular Signalling
- Vol. 143, 112470
APE1/Ref-1 redox function prevents VSMC phenotypic switching through KLF4 suppression
- Open Access
- 12 November 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (11) , 2767
Synergistic Inhibition of Triple-Negative Breast Cancer by Acetylsalicylic Acid and Recombinant Human APE1/Ref-1 in a Mouse Xenograft Model
Background: Triple-negative breast cancer (TNBC) is a highly aggressive subtype with limited therapeutic options due to the lack of estrogen, progesterone, and HER2 receptors. This study investigated the synergistic anticancer effects of recombinant human apurinic/apyrimidinic endonuclease 1/redox factor-1 (rhAPE1/Ref-1) and acetylsalicylic acid (ASA), a combination that has not been previously tested in vivo. Methods: We treated MDA-MB-231 TNBC cells with rhAPE1/Ref-1, ASA, or their combination to assess cell viability and apoptosis in vitro. In vivo, a murine xenograft model was established to evaluate the efficacy of the combination treatment on tumor growth, tumor-specific biomarkers, and key apoptotic proteins. The safety profile of the combination therapy was also assessed by monitoring hematological parameters. Results: While monotherapy with either rhAPE1/Ref-1 or ASA had minimal effects, their combination significantly reduced cell viability and enhanced apoptosis in vitro by increasing DNA fragmentation. These synergistic cytotoxic effects were significantly inhibited by the receptor for advanced glycation end-products (RAGE) siRNA, suggesting that RAGE acts as an important mediator. In the xenograft model, the combination treatment suppressed tumor growth by approximately 70%, an effect comparable to paclitaxel (PTX). This was confirmed by a significant reduction in the plasma levels of TNBC biomarkers (CEA, CA27-29, and CA15-3) and increased tumor apoptosis via the upregulation of p53 and Bax and downregulation of Bcl-2. Notably, ASA, alone or combined with rhAPE1/Ref-1, induced the expression of RAGE in MDA-MB-231 tumors. In contrast to PTX, the combination of rhAPE1/Ref-1 and ASA did not cause hematological toxicity, such as anemia or thrombocytopenia. Conclusions: The combination of rhAPE1/Ref-1 and ASA represents a promising new therapeutic strategy for TNBC by enhancing apoptosis and significantly inhibiting tumor progression in a mouse xenograft model.
- 12 November 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (11) , 2767
Open AccessSynergistic Inhibition of Triple-Negative Breast Cancer by Acetylsalicylic Acid and Recombinant Human APE1/Ref-1 in a Mouse Xenograft Model
Background: Triple-negative breast cancer (TNBC) is a highly aggressive subtype with limited therapeutic options due to the lack of estrogen, progesterone, and HER2 receptors. This study investigated the synergistic anticancer effects of recombinant human apurinic/apyrimidinic endonuclease 1/redox factor-1 (rhAPE1/Ref-1) and acetylsalicylic acid (ASA), a combination that has not been previously tested in vivo. Methods: We treated MDA-MB-231 TNBC cells with rhAPE1/Ref-1, ASA, or their combination to assess cell viability and apoptosis in vitro. In vivo, a murine xenograft model was established to evaluate the efficacy of the combination treatment on tumor growth, tumor-specific biomarkers, and key apoptotic proteins. The safety profile of the combination therapy was also assessed by monitoring hematological parameters. Results: While monotherapy with either rhAPE1/Ref-1 or ASA had minimal effects, their combination significantly reduced cell viability and enhanced apoptosis in vitro by increasing DNA fragmentation. These synergistic cytotoxic effects were significantly inhibited by the receptor for advanced glycation end-products (RAGE) siRNA, suggesting that RAGE acts as an important mediator. In the xenograft model, the combination treatment suppressed tumor growth by approximately 70%, an effect comparable to paclitaxel (PTX). This was confirmed by a significant reduction in the plasma levels of TNBC biomarkers (CEA, CA27-29, and CA15-3) and increased tumor apoptosis via the upregulation of p53 and Bax and downregulation of Bcl-2. Notably, ASA, alone or combined with rhAPE1/Ref-1, induced the expression of RAGE in MDA-MB-231 tumors. In contrast to PTX, the combination of rhAPE1/Ref-1 and ASA did not cause hematological toxicity, such as anemia or thrombocytopenia. Conclusions: The combination of rhAPE1/Ref-1 and ASA represents a promising new therapeutic strategy for TNBC by enhancing apoptosis and significantly inhibiting tumor progression in a mouse xenograft model.
- Open Access
- 28 October 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (11) , 2639
Endothelial Dysfunction: From Pathophysiology to Novel Therapeutic Approaches 2.0
Endothelial dysfunction (ED) is a multifactorial pathological process characterized by the loss of the endothelial physiological function, which is essential for maintaining vascular homeostasis
- 28 October 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (11) , 2639
Open AccessEndothelial Dysfunction: From Pathophysiology to Novel Therapeutic Approaches 2.0
Endothelial dysfunction (ED) is a multifactorial pathological process characterized by the loss of the endothelial physiological function, which is essential for maintaining vascular homeostasis
- Open Access
- 8 September 2025
- Published by The Korean Physiological Society and The Korean Society of Pharmacology in The Korean Journal of Physiology & Pharmacology
- Vol. 29 (6) , 699-711
Endothelial to mesenchymal transition: a central mechanism in diabetes-induced vascular pathology
Giang-Huong Vu, Byeong Hwa Jeon, and Cuk-Seong Kim. Korean J Physiol Pharmacol -0001;0:. https://doi.org/10.4196/kjpp.25.236
- 8 September 2025
- Published by The Korean Physiological Society and The Korean Society of Pharmacology in The Korean Journal of Physiology & Pharmacology
- Vol. 29 (6) , 699-711
Open AccessEndothelial to mesenchymal transition: a central mechanism in diabetes-induced vascular pathology
Giang-Huong Vu, Byeong Hwa Jeon, and Cuk-Seong Kim. Korean J Physiol Pharmacol -0001;0:. https://doi.org/10.4196/kjpp.25.236
- Open Access
- 19 May 2025
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
Apurinic/apyrimidinic endonuclease 1/redox factor-1 deficiency exacerbates renal fibrosis in a unilateral ureteral obstruction model
Background: The role of apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) in renal fibrosis development remains unclear. This study aimed to investigate the role of APE1/Ref-1 deficiency on renal fibrosis and elucidate the underlying mechanisms using a unilateral ureteral obstruction (UUO) mouse model and HK-2 cells in vitro. Methods: Male wild-type and heterozygous APE1/Ref-1 +/-mice underwent UUO or sham surgery. Renal tissue was collected at 7 and 14 days after UUO. APE1/Ref-1 expression, histological changes, fibrosis markers (collagen I, α-smooth muscle actin [α-SMA], vimentin, transforming growth factor-β1 [TGF-β1]), macrophage infiltration (F4/80, CD68), 8-hydroxy-2'-deoxyguanosine (8-OHdG), and apoptosis (terminal deoxynucleotidyl transferase dUTP nick end labeling [TUNEL]) were assessed. In human kidney-2 (HK-2) cells, APE1/Ref-1 was knocked down using small interfering RNA, and epithelial-mesenchymal transition (EMT) markers (vimentin, α-SMA) were evaluated following TGF-β1 stimulation. Results: UUO upregulated APE1/Ref-1 expression in wild-type mice, but this was attenuated in heterozygous APE1/Ref-1 +/-mice. While both genotypes displayed tubular injury, no significant differences in tubular injury scores or renal function markers were observed. Heterozygous APE1/Ref-1 +/-mice exhibited exacerbated renal fibrosis compared to wild-type mice, as shown by increased collagen I, α-SMA, TGF-β1, and vimentin levels. Macrophage infiltration (CD68, F4/80) was significantly elevated in heterozygous APE1/Ref-1 +/-mice after UUO. Increased 8-OHdG and TUNEL-positive cells indicated enhanced oxidative damage and apoptosis in heterozygous APE1/Ref-1 +/-mice. In HK-2 cells, APE1/Ref-1 knockdown induced the upregulation of vimentin and α-SMA, suggesting a role in EMT regulation. Conclusion: APE1/Ref-1 deficiency exacerbates fibrosis, macrophage infiltration, and apoptosis. APE1/Ref-1 also modulates EMT in vitro, highlighting its protective function in chronic kidney disease.
- 19 May 2025
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
Open AccessApurinic/apyrimidinic endonuclease 1/redox factor-1 deficiency exacerbates renal fibrosis in a unilateral ureteral obstruction model
Background: The role of apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) in renal fibrosis development remains unclear. This study aimed to investigate the role of APE1/Ref-1 deficiency on renal fibrosis and elucidate the underlying mechanisms using a unilateral ureteral obstruction (UUO) mouse model and HK-2 cells in vitro. Methods: Male wild-type and heterozygous APE1/Ref-1 +/-mice underwent UUO or sham surgery. Renal tissue was collected at 7 and 14 days after UUO. APE1/Ref-1 expression, histological changes, fibrosis markers (collagen I, α-smooth muscle actin [α-SMA], vimentin, transforming growth factor-β1 [TGF-β1]), macrophage infiltration (F4/80, CD68), 8-hydroxy-2'-deoxyguanosine (8-OHdG), and apoptosis (terminal deoxynucleotidyl transferase dUTP nick end labeling [TUNEL]) were assessed. In human kidney-2 (HK-2) cells, APE1/Ref-1 was knocked down using small interfering RNA, and epithelial-mesenchymal transition (EMT) markers (vimentin, α-SMA) were evaluated following TGF-β1 stimulation. Results: UUO upregulated APE1/Ref-1 expression in wild-type mice, but this was attenuated in heterozygous APE1/Ref-1 +/-mice. While both genotypes displayed tubular injury, no significant differences in tubular injury scores or renal function markers were observed. Heterozygous APE1/Ref-1 +/-mice exhibited exacerbated renal fibrosis compared to wild-type mice, as shown by increased collagen I, α-SMA, TGF-β1, and vimentin levels. Macrophage infiltration (CD68, F4/80) was significantly elevated in heterozygous APE1/Ref-1 +/-mice after UUO. Increased 8-OHdG and TUNEL-positive cells indicated enhanced oxidative damage and apoptosis in heterozygous APE1/Ref-1 +/-mice. In HK-2 cells, APE1/Ref-1 knockdown induced the upregulation of vimentin and α-SMA, suggesting a role in EMT regulation. Conclusion: APE1/Ref-1 deficiency exacerbates fibrosis, macrophage infiltration, and apoptosis. APE1/Ref-1 also modulates EMT in vitro, highlighting its protective function in chronic kidney disease.
- Open Access
- 7 May 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (9) , 4449
Non-Thermal Plasma Attenuates TNF-α-Induced Endothelial Inflammation via ROS Modulation and NF-κB Inhibition
Non-thermal plasma (NTP) has emerged as a promising therapeutic tool due to its anti-inflammatory properties; however, its molecular effects on vascular endothelial inflammation remain unclear. This study investigated the effects of NTP on tumor necrosis factor-alpha (TNF-α)-induced inflammation in human umbilical vein endothelial cells (HUVECs). NTP treatment significantly reduced intracellular reactive oxygen species (ROS) levels and downregulated the expression of adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), which are key markers of endothelial activation. In addition, NTP suppressed mRNA expression of pro-inflammatory cytokines, including TNF-α, interleukin-1 beta (IL-1β), and interleukin-6 (IL-6). Mechanistically, NTP inhibited the nuclear translocation of phosphorylated NF-κB p65, indicating attenuation of NF-κB signaling. These results demonstrate that NTP modulates inflammatory responses in endothelial cells by attenuating ROS generation and suppressing NF-κB-mediated signaling. Our findings suggest that NTP may serve as a potential therapeutic strategy for treating vascular inflammation and related pathologies.
- 7 May 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (9) , 4449
Open AccessNon-Thermal Plasma Attenuates TNF-α-Induced Endothelial Inflammation via ROS Modulation and NF-κB Inhibition
Non-thermal plasma (NTP) has emerged as a promising therapeutic tool due to its anti-inflammatory properties; however, its molecular effects on vascular endothelial inflammation remain unclear. This study investigated the effects of NTP on tumor necrosis factor-alpha (TNF-α)-induced inflammation in human umbilical vein endothelial cells (HUVECs). NTP treatment significantly reduced intracellular reactive oxygen species (ROS) levels and downregulated the expression of adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), which are key markers of endothelial activation. In addition, NTP suppressed mRNA expression of pro-inflammatory cytokines, including TNF-α, interleukin-1 beta (IL-1β), and interleukin-6 (IL-6). Mechanistically, NTP inhibited the nuclear translocation of phosphorylated NF-κB p65, indicating attenuation of NF-κB signaling. These results demonstrate that NTP modulates inflammatory responses in endothelial cells by attenuating ROS generation and suppressing NF-κB-mediated signaling. Our findings suggest that NTP may serve as a potential therapeutic strategy for treating vascular inflammation and related pathologies.
- Open Access
- 7 March 2025
- Published by The Korean Physiological Society and The Korean Society of Pharmacology in The Korean Journal of Physiology & Pharmacology
- Vol. 29 (3) , 293-305
Aspirin-induced acetylation of APE1/Ref-1 enhances RAGE binding and promotes apoptosis in ovarian cancer cells
Hao Jin, Yu Ran Lee, Sungmin Kim, Eun-Ok Lee, Hee Kyoung Joo, Heon Jong Yoo, Cuk-Seong Kim, and Byeong Hwa Jeon. Korean J Physiol Pharmacol 2025;29:293-305. https://doi.org/10.4196/kjpp.24.273
- 7 March 2025
- Published by The Korean Physiological Society and The Korean Society of Pharmacology in The Korean Journal of Physiology & Pharmacology
- Vol. 29 (3) , 293-305
Open AccessAspirin-induced acetylation of APE1/Ref-1 enhances RAGE binding and promotes apoptosis in ovarian cancer cells
Hao Jin, Yu Ran Lee, Sungmin Kim, Eun-Ok Lee, Hee Kyoung Joo, Heon Jong Yoo, Cuk-Seong Kim, and Byeong Hwa Jeon. Korean J Physiol Pharmacol 2025;29:293-305. https://doi.org/10.4196/kjpp.24.273
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Food Biochemistry
- Vol. 2025 (1)
Optimization of Catechin, Epicatechin, and 3,4‐Dihydroxybenzoic Acid Dosage Combinations to Improve Sperm Function in Lead‐Exposed Rats
Lead (Pb) exposure is a major environmental cause of male infertility, impairing sperm quality and testicular function. This study aimed to determine the optimal concentrations of the bioactive polyphenolic compounds (–)‐catechin (catechin), (–)‐epicatechin (EC), and 3,4‐dihydroxybenzoic acid (3,4‐DHB) for improving sperm function in Pb‐exposed male rats. Pb‐exposed rats were administered either each compound individually or combination regimens at low or high doses. Outcomes assessed included blood Pb levels, androgen receptor (AR) expression, sperm count, motility, and testicular histology. The high‐dose combination produced the most prominent improvements, including increased AR expression, enhanced spermatogenesis, and improved sperm count and motility. These findings suggest that the high‐dose combination may serve as a promising candidate for further investigation as a therapy for Pb‐induced male infertility.
- 1 January 2025
- Published by Wiley in Journal of Food Biochemistry
- Vol. 2025 (1)
Open AccessOptimization of Catechin, Epicatechin, and 3,4‐Dihydroxybenzoic Acid Dosage Combinations to Improve Sperm Function in Lead‐Exposed Rats
Lead (Pb) exposure is a major environmental cause of male infertility, impairing sperm quality and testicular function. This study aimed to determine the optimal concentrations of the bioactive polyphenolic compounds (–)‐catechin (catechin), (–)‐epicatechin (EC), and 3,4‐dihydroxybenzoic acid (3,4‐DHB) for improving sperm function in Pb‐exposed male rats. Pb‐exposed rats were administered either each compound individually or combination regimens at low or high doses. Outcomes assessed included blood Pb levels, androgen receptor (AR) expression, sperm count, motility, and testicular histology. The high‐dose combination produced the most prominent improvements, including increased AR expression, enhanced spermatogenesis, and improved sperm count and motility. These findings suggest that the high‐dose combination may serve as a promising candidate for further investigation as a therapy for Pb‐induced male infertility.